{"id":"W2614821999","doi":"10.1200/jco.2013.31.15_suppl.5039","title":"A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Dasatinib; Docetaxel; Oncology; Androgen deprivation therapy; N-terminal telopeptide; Urology; Gastroenterology; Cancer; Randomized controlled trial; Surgery; Alkaline phosphatase; Receptor; Osteocalcin; Tyrosine kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001966969,0.001974007,0.003272285,0.0006315435,0.0005235508,0.001292721,0.001137159,0.002184775,0.008141075],"category_scores_gemma":[0.001916766,0.001181571,0.001205939,0.0005938092,0.001727064,0.001471923,0.0005654074,0.003691062,0.001623383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009865523,"about_ca_system_score_gemma":0.001578539,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009033616,"about_ca_topic_score_gemma":0.002218074,"domain_scores_codex":[0.999295,0.0003610686,0.00003816414,0.0001313463,0.00004926539,0.0001251319],"domain_scores_gemma":[0.9986504,0.0002698895,0.0002368434,0.0001185708,0.00006918146,0.0006552535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9662015,0.01953906,0.000544696,0.0002161658,0.0002499324,0.00004475394,0.00004504048,0.0003112604,0.003311563,0.00008805539,0.0006007597,0.008847184],"study_design_scores_gemma":[0.8546143,0.1429764,0.001198975,0.00001038389,0.0001011813,0.00003798568,0.00001786326,0.0002614473,0.0002303626,0.0001184213,0.0004210146,0.00001158244],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836944,0.002010725,0.0006859062,0.0008611366,0.0006189281,0.008635516,0.00123915,0.0001348974,0.002119481],"genre_scores_gemma":[0.9811369,0.001623543,0.001783482,0.001604909,0.0005932449,0.00792582,0.001203225,0.00003021772,0.004098612],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008141075,"threshold_uncertainty_score":0.02723461,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1347098435390695,"score_gpt":0.5026620645599288,"score_spread":0.3679522210208592,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}